Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
US9968616B2 · kind B2 · utility
0Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 23, 2015 |
| Grant date | May 15, 2018 |
| Priority date | — |
| Expiry date | Oct 23, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.